Research for ScinoPharm Taiwan Announces Approval of Bortezomib Injection for Multiple Myeloma Treatment in Taiwan, Strengthening Domestic Pharmaceutical Supply Chain Resilience - aVenture Research
ScinoPharm Taiwan, Ltd.
ScinoPharm Taiwan Announces Approval of Bortezomib Injection for Multiple Myeloma Treatment in Taiwan, Strengthening Domestic Pharmaceutical Supply Chain Resilience
ScinoPharm Taiwan announced that it has successfully obtained marketing approval from the Taiwan Food and Drug Administration (TFDA) for Bortezomib, a treatment for Multiple Myeloma. Following the U.S. FDA approval secured in 2023, the newly granted Taiwan approval marks another significant milestone for the company. This achievement not only highlights ScinoPharm Taiwan's decades-long expertise in oncology drug development, but also demonstrates its concrete response to the government's policy